Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 10/20 | 0.64 |
| ▸ | BACE1 | P56817 | 2/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323374 | 1.00 | NCF1 (0.64) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL27826163 | 0.84 | BACE1 (0.57) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL28159979 | 0.82 | BACE1 (0.58) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL28107175 | 0.80 | NCF1 (0.46) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL1848398 | 0.78 | NCF1 (0.60) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL1845376 | 0.78 | NCF1 (0.60) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL482375 | 0.78 | BACE1 (0.60) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL1845788 | 0.78 | NCF1 (0.60) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL3094768 | 0.78 | BACE1 (1.00) | NCF1BACE1ACHEKDM4EALDH1A1 | |
| SCHEMBL31667822 | 0.78 | BACE1 (0.60) | NCF1BACE1ACHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117205212-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-12 | — | — | CN | claimed |
| CN-107207463-B | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-10-24 | — | — | CN | claimed |
| CN-110449178-B | Photocatalyst, preparation method and application thereof | 广州大学 | 2022-05-24 | — | — | CN | claimed |
| EP-4598532-A1 | COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS | Genfit (FR) | 2025-08-13 | — | — | EP | disclosed |
| US-20250177373-A1 | COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION | THE CHILDEREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| US-12064425-B2 | Compositions and methods for targeting a viral infection | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2024-08-20 | — | — | US | disclosed |
| EP-4349336-A1 | COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS | Genoscience Pharma (FR) | 2024-04-10 | — | — | EP | disclosed |
| CN-117568459-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117281805-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117205212-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-107207463-B | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-113845548-B | Platinum complex of quinazoline hydrazine dithioformate and preparation method and application thereof | 深圳大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114867528-A | Antibacterial quinolines | 社会医疗技术员技术股份公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114805341-A | Aromatic heterocyclic compounds and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110449178-B | Photocatalyst, preparation method and application thereof | 广州大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-110449178-B | Photocatalyst, preparation method and application thereof | 广州大学 | 2022-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177373-A1 | COMPOSITIONS AND METHODS FOR TARGETING A VIRAL INFECTION | HAVCR2, CD4, MAVS | NCF1 1375/4885BACE1 653/4885ACHE 3738/4885 |
| US-12064425-B2 | Compositions and methods for targeting a viral infection | HAVCR2, CD4, MAVS | NCF1 1375/4885BACE1 653/4885ACHE 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.